Regeneron ‘Shocked’ At Biogen Lucentis Biosimilar Sales
Biogen’s Byooviz Biosimilar Launched 1 July; Company Stressed Gradual Launch
With its own interests in the branded eye-disease space, Regeneron has commented on ranibizumab biosimilar sponsor Biogen’s fortunes during a recent conference.
You may also be interested in...
Samsung Bioepis has announced the launch of its SB11 ranibizumab biosimilar rival to Lucentis in Korea through partner Samil. The introduction – under the name Amelivu – comes after the product was launched as Byooviz in the US last year.
Having first expected to resubmit the filing by the end of this year, a delay to a key report means Xbrane now expects to deliver its new biologics license application to the FDA during Q1 2023.
In a small pool of developers, Biogen has matched Fresenius Kabi by filing its proposed tocilizumab biosimilar with the US Food and Drug Administration.